References
- Roujeau JC, Bioulac-Sage P, Bourseau C, Guillaume JC, Bernard P, Lok C, et al. Acute generalized exanthematous pustulosis. Analysis of 63 cases. Arch Dermatol. 1991; 127: 1333–8
- Sidoroff A, Dunant A, Viboud C, Halevy S, Bavinck JN, Naldi L, et al. Risk factors for acute generalized exanthematous pustulosis (AGEP) – results of a multinational case-control study (EuroSCAR). Br J Dermatol. 2007; 157: 989–96
- Williams JDL, Griffiths CEM. Cytokine blocking agents in dermatology. Clin Exp Dermatol. 2002; 27: 585–90
- Tyring S, Gordon KB, Poulin Y, Langley RG, Gottlieb AB, Dunn M, et al. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. Arch Dermatol. 2007; 143: 719–26
- Saito K, Mori S, Tanda N, Sakamoto S. Expression of p53 protein and Ki-67 antigen in gingival hyperplasia induced by nifedipine and phenytoin. J Periodontol. 1999; 70: 581–6
- Famularo G, Di Dona B, Canzona F, Girardelli CR, Cruciani G. Etanercept for toxic epidermal necrolysis. Ann Pharmacother. 2007; 41: 1083–4
- Meiss F, Helmbold P, Meykadeh N, Gaber G, Marsch WCh, Fischer M. Overlap of acute generalized exanthematous pustulosis and toxic epidermal necrolysis: Response to antitumour necrosis factor-alpha antibody infliximab: Report of three cases. J Eur Acad Dermatol Venereol. 2007; 21: 717–19
- Al-Shouli S, Abouchala N, Bogusz MJ, Al Tufail M, Thestrup-Pedersen K. Toxic epidermal necrolysis associated with high intake of sildenafil and its response to infliximab. Acta Derm Venereol. 2005; 85: 534–5
- Lerch M, Pichler WJ. The immunological and clinical spectrum of delayed drug-induced exanthems. Curr Opin Allergy Clin Immunol. 2004; 4: 411–19
- Sidoroff A, Halevy S, Bavnick JN, Vaillant L, Roujeau JC, et al. Acute generalized exanthematous pustulosis (AGEP) – a clinical reaction pattern. J Cutan Pathol. 2001; 28: 113–19
- De Coninck AL, Van Strubarq AS, Pipeleers-Marichal MA, Huyghens LP, Suys ET, Roseeuw DI. Acute generalized exanthematous pustulosis induced by paracetamol: A case with severe hemodynamic disturbances. Dermatology. 1996; 193: 338–41
- Scheinfeld N, Wesson K, Perry P, Weinberg J. Acute generalized exanthematous pustulosis resembling toxic epidermal necrolysis caused by famotidine. Acta Derm Venereol. 2003; 83: 76–7
- Freedberg IM, Eisen AZ, Wolff K, Austen KF, Goldsmith LA, Katz SI. Fitzpatrick's dermatology in general medicine.6th ed. McGraw-Hill, New York 2003; 625–7
- Frederic JE, Nesbitt LT. Adverse cutaneous drug eruptions. Infectious diseases: Emergency department diagnosis and management.1st ed., EM Slaven, SC Stone, FA Lopez. McGraw-Hill, NewYork 2007; 226–36
- Roujeau JC. Clinical heterogeneity of drug hypersensitivity. Toxicology. 2005; 15:209: 123–9
- Hunger RE, Hunziker T, Buettiker U, Braathen LR, Yawalkar N. Rapid resolution of toxic epidermal necrolysis with anti-TNF-alpha treatment. J Allergy Clin Immunol. 2005; 116: 923–4
- Fischer M, Fiedler E, Marsch WC, Wohlrab J. Antitumour necrosis factor-alpha antibodies (infliximab) in the treatment of a patient with toxic epidermal necrolysis. Br J Dermatol. 2002; 146: 707–9